Hengrui Pharma Licenses Weight-Loss Drug to Novo Nordisk in $2.6 Billion Deal
Beijing:Chinese drugmaker Hengrui Pharma has announced an agreement to license the global rights of its experimental weight-loss drug, HRS-1596, to Denmark’s Novo Nordisk. The deal is potentially valued at up to $2.6 billion.
According to Anadolu Ag…